Liven Pharma Limited
Shariah compliantAlmost no debt, a good business and priced below its peers. No read is against it.
Working
- P/E 0.0 against a sector median of 11.9.
- Debt is 3% of equity in the latest quarter.
- Revenue up 62% on the same quarter last year.
To watch
- Free cash flow negative, Rs 18m out last year, after Rs 152m the year before.
- A loss of Rs 31m in the latest year, after a loss of Rs 12m over three years.
Keep reading LIVEN: business, price trend and value
How good the business is, where its support zone sits, what it may be worth, its health, dividends, peers and latest results open with a free account.
Latest results
Quarter: Jul–Sep 2026In the Jul–Sep 2026 quarter, LIVEN's sales rose 62% to Rs 14.3mn, from Rs 8.8mn, and profit after tax was a loss of Rs 7.4mn, against a loss of Rs 30.2mn (compared with Jul–Sep 2025).
Earnings per share were -Rs 0.07, against -Rs 0.32 a year earlier.
- Dividend payout
- 0%
- of earnings
- Return on equity
- -1%
- Net margin
- -8.0%
- last 12 months
- Debt to equity
- 0.03
LIVEN quarterly results
Reported figures| Quarter | Sales | Profit after tax | Net margin | EPS | Dividend / share |
|---|---|---|---|---|---|
| Jul–Sep 2026 | Rs 14.3mn | -Rs 7.4mn | -51.6% | -Rs 0.07 | — |
| Apr–Jun 2026 | Rs 13.2mn | -Rs 25.2mn | -191.5% | -Rs 0.23 | — |
| Jan–Mar 2026 | Rs 29.2mn | -Rs 4.0mn | -13.5% | -Rs 0.03 | — |
| Oct–Dec 2025 | Rs 54.6mn | Rs 28.2mn | 51.7% | Rs 0.30 | — |
| Jul–Sep 2025 | Rs 8.8mn | -Rs 30.2mn | -341.9% | -Rs 0.32 | — |
| Apr–Jun 2025 | Rs 6.5mn | -Rs 695.3mn | -10727.4% | -Rs 10.76 | — |
| Jan–Mar 2025 | Rs 14.8mn | -Rs 9.6mn | -65.2% | -Rs 0.13 | — |
| Oct–Dec 2024 | Rs 17.1mn | -Rs 9.5mn | -55.4% | -Rs 0.20 | — |
LIVEN annual results and dividends
Reported figures| Year | Sales | Profit after tax | EPS | Dividend / share |
|---|---|---|---|---|
| Year to Jun 2026 | Rs 105.8mn | -Rs 31.1mn | -Rs 0.28 | — |
| Year to Jun 2025 | Rs 127.3mn | -Rs 585.7mn | -Rs 8.44 | — |
| Year to Jun 2024 | — | Rs 41.7mn | Rs 3.44 | — |
| Year to Jun 2023 | — | -Rs 12.3mn | -Rs 1.02 | — |
| Year to Jun 2022 | — | -Rs 14.3mn | -Rs 1.18 | — |
Balance sheet and price
Balance sheet as of Sep 2026- Total assets
- Rs 1.2bn
- Shareholders' equity
- Rs 978.1mn
- Cash & bank
- Rs 8.4mn
- Total debt
- Rs 33.1mn
- Current ratio
- 2.58
- 3-month high
- Rs 47.64
- 3-month low
- Rs 29.01
- 1-month change
- +51.5%
- 3-month change
- +40.8%
Read more about LIVEN
Other pharmaceuticals companies
- ABOTAbbot Laboratories (Pakistan) LtdRs 924.15P/E 11.1
- AGPAGP LtdRs 149.85P/E 12.7
- BFBIOBF Biosciences LtdRs 123.20P/E 20.0
- CPHLCiti Pharma LtdRs 63.42P/E 15.7
- CWHCCrestwell Healthcare LimitedRs 21.35
- FEROZFerozsons Laboratories LtdRs 337.68P/E 16.4
- GLAXOGlaxoSmithKline Pakistan LtdRs 315.00P/E 10.4
- HALEONHaleon Pakistan LtdRs 658.64P/E 12.7
- HINOONHighnoon Laboratories LtdRs 956.76P/E 12.1
- HPLHoehcst Pakistan LtdRs 4056.91P/E 10.4
- IBLHLIBL HealthCare LtdRs 39.86P/E 19.1
- MACTERMacter International LtdRs 244.00P/E 15.3
LIVEN: common questions
What is LIVEN's share price?
Liven Pharma Limited (LIVEN) last closed at Rs 47.64 on the Pakistan Stock Exchange.
Does LIVEN pay a dividend?
Liven Pharma Limited reported no dividend for the year to Jun 2026.
What were LIVEN's latest results?
In the Jul–Sep 2026 quarter, LIVEN's sales rose 62% to Rs 14.3mn, from Rs 8.8mn, and profit after tax was a loss of Rs 7.4mn, against a loss of Rs 30.2mn (compared with Jul–Sep 2025).
Figures are taken from the company's published financial statements and PSX prices. This page is information, not investment advice.

